Regeneron Pharmaceuticals Drops as FDA Approval for Dupixent Weighs on Shares
REGN faces mixed market reactions post-FDA approval of Dupixent. Understanding this event's implications is crucial for investors considering REGN.
Yahoo Finance · 4 min read